Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

TECHNIA AB

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...

Fundamental Aspects of Airy Disk Patterns

Knowledge Article from ZEISS.

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

RFK Jr: I september vet vi vad som orsakar autism

USA ska identifiera orsaken till autism – och det ska vara gjort till september i år. Det säger USA:s hälsominister Robert F. Kennedy Jr., som därmed sätter en ...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

KI-studie: Nässköljning kunde ge information om KOL

Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

ZEISS at EMO Hannover 2025

Experience some of the most exciting highlights from our ZEISS product portfolio.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Revealing the secrets of a part

CT inspection in automation technology at Festo.